MYOS RENS Technology Inc. Launches Collegiate Sports Marketing Platform

CEDAR KNOLLS, N.J., Nov. 8, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and owner of Fortetropin^®, the natural food product that helps build lean muscle, today announced the debut of its collegiate sports marketing platform promoting the benefits of muscle health.

Through a sponsorship deal with IMG College, a division of IMG, MYOS will market its products to a key demographic– collegiate athletic programs and their fans.

"IMG College has a large national footprint across collegiate athletics that can open the way for us to reach not only the athletic departments but also the faculty and alumni," said Joseph Mannello, Chief Executive Officer of MYOS. "Sports nutrition is a significant focus of MYOS and we are proud to offer an all-natural nutrition product that has been clinically shown to help the body build lean muscle. There has never been a greater commitment towards health and nutrition on college campuses and in athletics as there is today.  Our products are BSCG-certified drug free and WADA-compliant, and are ideal for sports programs."

"We are thrilled that MYOS has chosen to invest in the college space which continues to deliver a vibrant, passionate and loyal audience," said Tim Pernetti, President, IMG College. "We know that MYOS recognizes the tremendous value in collegiate athletics and we look forward to working with them in this innovative partnership."

MYOS is building a solid foundation for future advancements into key audiences through college sports, giving them a platform to potentially take Fortetropin® into additional sports markets, including various professional programs.

IMG College represents more than 200 colleges across multimedia rights, licensing and sponsorships. In addition, through relationships with major universities, conferences, and events, it provides leading brands with multi-channel platforms to connect with college sports fans at the national, regional, and local levels.

About MYOS RENS Technology Inc. 

MYOS RENS Technology (MYOS), "The Muscle Company™", is a Cedar Knolls, NJ-based bionutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, the world's first clinically-demonstrated myostatin reducer. Myostatin is a natural regulatory protein, which inhibits muscle growth. Fortetropin® is a fertilized egg yolk based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin® has been clinically shown to increase muscle size and lean body mass in conjunction with resistance training. MYOS believes Fortetropin® has the potential to redefine existing standards of physical health and wellness. For more information, please visit www.MYOSRENS.com

Forward-Looking Statements

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the successful launch of our products, including Qurr® products, the success of our research and development, the results of the clinical evaluation of Fortetropin^® and its effects, the ability to enter into partnership opportunities, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: [email protected]

SOURCE MYOS RENS Technology

Related Links

http://www.myosrens.com